Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Preclinical
Recipient : Orexo
Deal Size : Inapplicable
Deal Type : Inapplicable
Orexo Announces Positive Data for Powder-based Intranasal Vaccine
Details : Abera's influenza vaccine candidate is administered intranasally, either formulated as a liquid nasal solution or as an intranasal powder using Orexo's AmorphOX technology.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 10, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Recipient : Orexo
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
